Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL
Status:
Completed
Trial end date:
2021-08-05
Target enrollment:
Participant gender:
Summary
This is an open-label non-randomized two-center phase 2 study evaluating the safety and
efficacy of concurrent therapy with ibrutinib and venetoclax in subjects with relapsed or
refractory CLL/SLL.